Nektar Therapeutics (NKTR) reported third-quarter 2026 revenue of $9.4 million and a net loss of $55.7 million, or $1.63 per basic and diluted share. Revenue was $11.8 million and net loss was $35.5 million in the prior-year quarter.
Cash and investments in marketable securities totaled $952.9 million at September 30, 2026. The company said it has initiated all three Phase 3 ZENITH AD registrational trials for rezpegaldesleukin in atopic dermatitis and plans to begin its ZENITH AA trial in alopecia areata in December.
- Third-quarter total revenue was $9.386 million, compared with $11.790 million a year earlier.
- Research and development expense was $44.123 million, up from $27.252 million in the third quarter of 2025.
- Total operating costs and expenses were $67.188 million, compared with $43.462 million a year earlier.
- Initial topline data from the ZENITH AD program are expected in mid-2028, with a BLA submission targeted for 2029.
$NKTR Insider Trading Activity
$NKTR insiders have traded $NKTR stock on the open market 10 times in the past 6 months. Of those trades, 0 have been purchases and 10 have been sales.
Here’s a breakdown of recent trading of $NKTR stock by insiders over the last 6 months:
- HOWARD W ROBIN (President & CEO) has made 0 purchases and 6 sales selling 20,862 shares for an estimated $1,274,229.
- JONATHAN ZALEVSKY (Chief R&D Officer) has made 0 purchases and 4 sales selling 11,604 shares for an estimated $760,306.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$NKTR Hedge Fund Activity
We have seen 159 institutional investors add shares of $NKTR stock to their portfolio, and 100 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BLACKROCK, INC. added 2,249,201 shares (+324.7%) to their portfolio in Q2 2026, for an estimated $157,016,721
- STATE STREET CORP added 862,623 shares (+94.8%) to their portfolio in Q3 2026, for an estimated $52,227,509
- VESTAL POINT CAPITAL, LP added 715,000 shares (+250.9%) to their portfolio in Q2 2026, for an estimated $49,914,150
- BRAIDWELL LP added 473,617 shares (+inf%) to their portfolio in Q2 2026, for an estimated $33,063,202
- GILDER GAGNON HOWE & CO LLC added 329,115 shares (+121.1%) to their portfolio in Q2 2026, for an estimated $22,975,518
- DEEP TRACK CAPITAL, LP added 300,000 shares (+inf%) to their portfolio in Q2 2026, for an estimated $20,943,000
- SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P. added 284,971 shares (+inf%) to their portfolio in Q2 2026, for an estimated $19,893,825
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
